--- title: "Citius Pharmaceuticals (CTXR) news: going concern and offering" url: "https://aibio.space/companies/citius-pharmaceuticals/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CTXR going concern and offering news: Citius Pharmaceuticals prices $5 million registered direct offering at $0.985. Citius Pharmaceuticals, Inc." --- CTXR Citius Pharmaceuticals, Inc. NASDAQ · United States # Citius Pharmaceuticals (CTXR) news CTXR going concern and offering news Listings · 2026-10-23 ## [Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price](https://aibio.space/news/citius-oncology-gets-nasdaq-extension-april-19-2027-bid-price/) Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million. ## Latest Citius Pharmaceuticals news 1. 2026-08-21 Listings [Citius Pharmaceuticals gets Nasdaq extension to February 8, 2027 on bid price](https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-extension-february-8-2027-bid-price/) Nasdaq gave Citius Pharmaceuticals until February 8, 2027 to show compliance with its $1.00 minimum bid price. The 8-K gives no closing price and no plan, and the company says it cannot assure it will regain compliance. 2. 2026-04-24 Financings [Citius Pharmaceuticals prices $5 million registered direct offering at $0.985](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/) Citius Pharmaceuticals sold 4,730,457 shares at $0.985 and pre-funded warrants for 345,686 shares, and it will issue warrants at $0.86 a share. The prospectus supplement also reports substantial doubt about its ability to continue as a going concern. 3. 2026-02-13 Listings [Citius Pharmaceuticals gets Nasdaq minimum bid price notice; compliance deadline is August 10, 2026](https://aibio.space/news/citius-pharmaceuticals-gets-nasdaq-minimum-bid-price-notice-compliance/) Nasdaq told Citius Pharmaceuticals on February 9, 2026 that its stock had closed below $1.00 for 30 consecutive business days, and the company has until August 10, 2026 to regain compliance. The same filing reports $3.9 million in first-quarter revenue from LYMPHIR, against $7.7 million in cash. 4. 2025-05-14 Distress [Citius Oncology 10-Q cites auditor's going-concern doubt](https://aibio.space/news/citius-oncology-10-q-cites-auditors-going-concern-doubt/) Citius Oncology reported $112 in cash at March 31, 2025 and negative working capital of about $31.7 million. Its parent had sufficient capital to fund it only through May 2025, and Nasdaq gave it until October 20, 2025 to fix its bid price. 5. 2025-05-14 Distress [Citius Pharmaceuticals 10-Q cites going-concern doubt and Nasdaq compliance](https://aibio.space/news/citius-pharmaceuticals-10-q-cites-going-concern-doubt-nasdaq/) The company had $26,410 in cash at March 31, 2025. Its own estimate says cash, including $1.735 million of net proceeds from an April offering, lasts only through May 2025, and it lost $21,792,751 in the six months to March 31. 6. 2025-04-18 Financings [Citius Pharmaceuticals sells CEO one Series A preferred share for $100 ahead of share vote](https://aibio.space/news/citius-pharmaceuticals-sells-ceo-one-series-preferred-share-100-ahead/) Citius Pharmaceuticals sold one share of a newly designated Series A preferred stock for $100 to Chairman and CEO Leonard Mazur on April 17, 2025. The share carries 1,000,000,000 votes on a proposal to raise authorized common shares from 16,000,000 to 250,000,000, and the board also cut the quorum for stockholder meetings to one-third. 7. 2025-02-14 Listings [Citius Pharmaceuticals reports $1.1 million cash and expects to raise capital](https://aibio.space/news/citius-pharmaceuticals-reports-1-1-million-cash-expects-raise-capital/) Citius Pharmaceuticals ended its fiscal first quarter with $1,100,079 in cash, after operations used $4,725,852 and inventory absorbed $6,112,603. The release does not name a placement agent for the offerings it describes. 8. 2025-01-06 Distress [Citius Oncology hires Jefferies to explore strategic alternatives](https://aibio.space/news/citius-oncology-hires-jefferies-explore-strategic-alternatives/) Citius Oncology has set no timeline for its strategic review, and the release says there is no assurance it will produce a deal. Its parent owns 92% of the company and has funded it since the subsidiary was formed. ## Citius Pharmaceuticals at a glance - **Ticker**: CTXR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $17.0 million ### Related companies - [Creative Medical Technology Holdings](https://aibio.space/companies/creative-medical-technology/) NASDAQ: CELZ - [Lantheus Holdings](https://aibio.space/companies/lantheus/) NASDAQ: LNTH - [Valion Bio](https://aibio.space/companies/valion-bio/) NASDAQ: VBIO - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [Dyadic International](https://aibio.space/companies/dyadic-international/) NASDAQ: DYAI - [Polaryx Therapeutics](https://aibio.space/companies/polaryx-therapeutics/) NASDAQ: PLYX - [Apollomics](https://aibio.space/companies/apollomics/) NASDAQ: APLM ### Also on NASDAQ - [Greenland Mines](https://aibio.space/companies/greenland-mines/) GRML - [Niki BioSolutions](https://aibio.space/companies/niki-biosolutions/) NIKI - [Vistagen Therapeutics](https://aibio.space/companies/vistagen-therapeutics/) VTGN - [Alamar Biosciences](https://aibio.space/companies/alamar-biosciences/) ALMR - [IM Cannabis](https://aibio.space/companies/im-cannabis/) IMCC - [Zhengye Biotechnology Holding](https://aibio.space/companies/zhengye-biotechnology/) ZYBT ## Citius Pharmaceuticals annual financials | Line | FY ended Sep 30, 2025 | FY ended Sep 30, 2024 | |---|---|---| | Research and development | [$9.2 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/) | [$11.9 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/) | | Cash from operations | [-$26.6 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/) | [-$28.2 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/) | | Cash and equivalents | [$4.3 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090185/) | [$3.3 million](https://www.sec.gov/Archives/edgar/data/1506251/000121390025125333/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $17.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Citius Pharmaceuticals Has Citius Pharmaceuticals issued a going-concern warning? Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/). Has Citius Pharmaceuticals raised money recently? Our latest story on this, dated Apr 24, 2026: "Citius Pharmaceuticals prices $5 million registered direct offering at $0.985". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/). What is the ticker symbol of Citius Pharmaceuticals? Citius Pharmaceuticals, Inc. trades under the ticker CTXR on NASDAQ. Where is Citius Pharmaceuticals listed? Citius Pharmaceuticals, Inc. is listed on NASDAQ. What is the SEC CIK of Citius Pharmaceuticals? The SEC Central Index Key (CIK) for Citius Pharmaceuticals, Inc. is 1506251. Its filings are on SEC EDGAR. How many shares does Citius Pharmaceuticals have outstanding? 27,452,570 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Citius Pharmaceuticals listed under? Our directory records Citius Pharmaceuticals, Inc. under United States. What does Citius Pharmaceuticals do? Our directory classifies Citius Pharmaceuticals, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Citius Pharmaceuticals? The ISIN recorded for Citius Pharmaceuticals, Inc. is US17322U3068. Does aibio.space cover Citius Pharmaceuticals? aibio.space lists Citius Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Citius Pharmaceuticals incorporated? SEC records list its state or country of incorporation as NV. How much does Citius Pharmaceuticals spend on research and development? $9.2 million in the fiscal year ended Sep 30, 2025, per its annual report. How much cash does Citius Pharmaceuticals have? $17.0 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Citius Pharmaceuticals (CTXR) stock news? Our latest story on Citius Pharmaceuticals, dated Oct 23, 2026: "Citius Oncology gets Nasdaq extension to April 19, 2027 on bid price". Citius Oncology has until April 19, 2027 to show a closing bid of $1.00 or more for ten consecutive business days. Its parent owned about 77.9% of the company in December 2025, and fiscal 2025 cash used in operations was $5.5 million against a net loss of $24.8 million. [Source](https://aibio.space/news/citius-oncology-gets-nasdaq-extension-april-19-2027-bid-price/). How long will Citius Pharmaceuticals's cash last? From our story of Apr 24, 2026: The prospectus supplement also reports substantial doubt about its ability to continue as a going concern. [Source](https://aibio.space/news/citius-pharmaceuticals-prices-5-million-registered-direct-offering-0/). ## Investor discussion: Citius Pharmaceuticals Members talk about Citius Pharmaceuticals (CTXR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Citius Pharmaceuticals, newest first. Each line links the filing it comes from. 1. 2026-08-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/ea0302856-8k_citius.htm) 2. 2026-04-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390026047296/ea0287618-424b5_citius.htm) 3. 2026-02-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390026015895/ea027694801ex99-1_citius.htm) 4. 2025-10-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025100559/ea0261895-424b5_citius.htm) 5. 2025-07-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025062099/ea024833501ex99-1_citius.htm) 6. 2025-06-11 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025053274/ea0245310-424b5_citius.htm) 7. 2025-05-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025049550/ea0244023-8k_citius.htm) 8. 2025-05-14 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025043360/ea0241638-10q_citius.htm) 9. 2025-04-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025033366/ea0238657-8k_citius.htm) 10. 2025-04-02 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025027540/ea0236354-424b5_citius.htm) 11. 2025-02-14 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025014359/ea023124501ex99-1_citius.htm) 12. 2025-01-08 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390025001826/ea0227128-424b5_citius.htm) 13. 2024-12-27 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390024113149/ea0225656-10k_citius.htm) 14. 2024-12-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390024111212/ea0225393-8k_citius.htm) 15. 2024-11-26 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390024102833/ea022238001ex99-1_citius.htm) 16. 2024-11-18 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390024099369/ea0221571-424b5_citius.htm) 17. 2024-11-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1506251/000121390024097495/ea0221050-8k_citius.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CTXR on TradingView](https://www.tradingview.com/symbols/NASDAQ-CTXR/). ## SEC filings and registration - **SEC name**: Citius Pharmaceuticals, Inc. - **CIK**: 1506251 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CTXR (Nasdaq) - **State or country of incorporation**: NV - **Fiscal year ends**: September 30 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11 COMMERCE DRIVE, CRANFORD, NJ, 07016 - **Phone**: (908) 967-6676 - **Shares outstanding**: 27,452,570 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: Trail One, Inc.; TrailOne, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390026092604/ea0302856-8k_citius.htm) filed 2026-08-21 - [10-Q](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090185/ea0301919-10q_citius.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090181/ea0302227-8k_citius.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390026085432/ea0300373-8k_citius.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390026063531/ea0292904-8k_citius.htm) filed 2026-06-01 - [S-3](https://www.sec.gov/Archives/edgar/data/1506251/000121390026060644/ea0291448-s3_citius.htm) filed 2026-05-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057876/ea0291037-8k_citius.htm) filed 2026-05-15 - [10-Q](https://www.sec.gov/Archives/edgar/data/1506251/000121390026057842/ea0290552-10q_citius.htm) filed 2026-05-15 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001506251), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Citius Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CTXR, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Citius Pharmaceuticals, Inc. - **Ticker**: CTXR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US17322U3068 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CTXR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/citius-pharmaceuticals/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Citius Pharmaceuticals (CTXR) news: going concern and offering", 2026-10-31, https://aibio.space/companies/citius-pharmaceuticals/